Search Results

Strategic Investments in the EU and US strengthen Vetter’s Global Footprint • Building permit application for German site submitted • Construction start is scheduled for the 2nd quarter 2026, with operational readiness in 2031 • Expansions in the US and Europe are included in a €1.5 billion investment plan

Independent recognition strengthens Vetter’s position as a trusted, high-performing CDMO • Awards recognize CDMO performance in five categories • Selection is based on quantitative metrics and verified sponsor feedback from biopharma partners • Recognition reflects trust placed in Vetter by industry and customers

Pharmaceutical service provider receives prestigious management award for the seventh year in a row · Family-owned company once again excels in all four key business areas · Site development and digitalization as strategic investment priorities · Focus on new sources for skilled workers and on lifelong learning

Further advancements in Europe and the US increase capacity and process efficiency ● Construction of new clinical manufacturing facility in Des Plaines on schedule ● Established Skokie site with ongoing strong performance for biotech partners ● Infrastructure upgrades at Austrian site further streamline customers’ path to clinic

Eli Lilly is the first pharma company to take first place in both categories in the eight years that intelligence firm IDEA Pharma has put out its analysis. Skyrocketing sales and multiple FDA approvals helped the company shoot to the top.

Recent deals from Pfizer and Bristol Myers Squibb hint at Big Pharma’s more collaborative approach to partnering with Chinese companies.

Three pharma CEOs joined the $30 million compensation club in 2025 but Eli Lilly’s David Ricks exceeded his nearest peer by more than $4 million.